November 28, 2023
Novo Nordisk Invested EUR 2.1 Billion in a French Manufacturing Site to Meet Growing Demand for Diabetes and Obesity Therapies
In a strategic move to address the escalating demand for its diabetes and obesity therapies, Novo Nordisk, a global healthcare company, has announced a significant investment of EUR 2.1 billion (USD 2.3 billion) in expanding its manufacturing facility in Chartres, France. This capital infusion aligns with Novo Nordisk’s commitment to increasing production capacity for key
